CFTR and Gastrointestinal Cancers: An Update.

Area of Science:

• Gastroenterology
• Oncology
• Genetics

Background:

• Cystic Fibrosis (CF) is a genetic disorder caused by mutations in the CFTR gene, impacting multiple organs including the GI tract.
• CFTR dysfunction is implicated in carcinogenesis, increasing cancer risk in CF patients, particularly GI cancers.
• CFTR also functions as a tumor suppressor in sporadic epithelial cancers, often silenced by epigenetic mechanisms.

Purpose of the Study:

• To review current research on the link between CFTR deficiency and GI cancers in both CF patients and sporadic cases.
• To explore how CFTR deficiency alters the tissue environment, promoting cancer development.
• To examine molecular pathways involved in CFTR regulation and downstream effects of CFTR deficiency in cancer.

Main Methods:

• Literature review of recent studies on CFTR, GI cancers, and epigenetic regulation.
• Analysis of molecular pathways, including Wnt/β-catenin and NF-κB signaling.
• Discussion of emerging CFTR modulator therapies and their potential impact on cancer.

Main Results:

• CFTR deficiency contributes to GI cancer development through mechanisms like barrier disruption, microbial imbalance, and inflammation.
• Epigenetic silencing of CFTR is a key factor in sporadic GI cancers.
• Dysregulation of Wnt/β-catenin and NF-κB pathways are downstream consequences of CFTR deficiency.

Conclusions:

• CFTR deficiency is a significant factor in both CF-related and sporadic GI cancers.
• Understanding CFTR's role in cancer provides insights into novel therapeutic strategies.
• CFTR modulator drugs show promise for personalized cancer medicine in GI malignancies.